ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/proteasome
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/proteasome
17
trial(s) found.
NCT07764978
Haem
Phase 3
Recruiting
Phase III Open-Label, Randomised Study of Consolidation With AZD0120 (Dual-Targeting BCMA/CD19 CAR-T) vs Continuous Standard Therapy in NDMM Patients Ineligible for ASCT as Initial Therapy (
DURGA-5
)
autologous CAR-T-cell therapy,BCMA/CD19-targeting
+ cancer therapy,proteasome-targeting
Multiple myeloma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2139 - Concord - Concord Repatriation General Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3002 - East Melbourne - Epworth Freemasons
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07728188
Haem
Phase 3
Not yet recruiting
A Phase 3, Multicenter, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etentamig in Combination With Pomalidomide Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (2L+ RRMM) (
M22-538
)
bispecific T-cell engager,BCMA-targeting
immunomodulatory imide drug
+ cancer therapy,proteasome-targeting
Multiple myeloma
NSW
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4217 - Benowa - Pindara Private Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NCT07391657
Haem
Phase 3
Recruiting
A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CART) Therapy Directed Against BCMA and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma. (
DURGA-4
)
autologous CAR-T-cell therapy,BCMA/CD19-targeting
+ cancer therapy,proteasome-targeting
Multiple myeloma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2050 - Camperdown - Chris O'Brien Lifehouse
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07224672
Haem
Phase 2
Recruiting
A Phase 2, Open-label, Randomized, Dose Optimization Study Evaluating the Efficacy and Safety of Belantamab Mafodotin Administered in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain Amyloidosis (
ALANIS
)
alkylating agent
anti-BCMA-immunoconjugate
glucocorticoid
proteasome inhibitor
AL amyloidosis
NSW
2145 - Westmead - The Children's Hospital at Westmead
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT07222761
Haem
Phase 3
Recruiting
An Open-Label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab Plus Carfilzomib Versus Standard of Care Combination Regimens in Patients With Relapsed/Refractory Multiple Myeloma (
LINKER-MM5
)
bispecific T-cell engager,BCMA-targeting
proteasome inhibitor
Multiple myeloma
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4215 - Southport - Gold Coast University Hospital
NCT06892522
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of T Cell Engaging Bi/Tri-specific Antibodies in Subjects With MM (
M25-059
)
CELMoD agent
Carfilzomib
Daratumumab
Dexamethasone
Etentamig
Iberdomide
Lenalidomide
Mezigdomide
anti-CD38 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
cancer therapy
cancer therapy,BCMA-targeting
cancer therapy,CD38-targeting
cancer therapy,cereblon-targeting
cancer therapy,proteasome-targeting
cereblon E3 ligase modulator
cereblon modulator
glucocorticoid
immuno-oncology therapy,BCMA-targeting
immuno-oncology therapy,CD38-targeting
immunomodulatory imide drug
proteasome inhibitor
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
+ cancer therapy,proteasome-targeting
Multiple myeloma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6005 - West Perth - Perth Blood Institute
NCT06615479
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (
CA088-1007
)
autologous CAR-T cell therapy,GPRC5D-targeting
immunomodulatory imide drug
+ cancer therapy,proteasome-targeting
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06152575
Haem
Phase 3
Recruiting
A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE (PVd) OR CARFILZOMIB, DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTI-CD38 DIRECTED THERAPY (
C1071032
)
anti-CS1 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NSW
2139 - Concord - Concord Repatriation General Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05669989
Haem
Phase 2
Enrolling by invitation
International, Multi-center, Open-label, Treatment Extension Study in Patients With Multiple Myeloma Who Are Still Benefitting From Isatuximab-based Therapy Following Completion of a Phase 1, 2, or 3 Parental Study (
LTS17704
)
anti-CD38 monoclonal antibody
+ cancer therapy,proteasome-targeting
Multiple myeloma
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2500 - Wollongong - Wollongong Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT05623020
Haem
Phase 3
Recruiting
AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + BORTEZOMIB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (
MagnetisMM-6
)
anti-CD38 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
VIC
3002 - East Melbourne - Epworth Freemasons
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3121 - Richmond - Epworth Freemasons Hospital
QLD
4217 - Benowa - Pindara Private Hospital
NZ
NZ.0622 - Takapuna - North Shore Hospital
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NCT05519085
Haem
Phase 3
Recruiting
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM):
SUCCESSOR-1
cereblon E3 ligase modulator
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Cancer Care Wollongong
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.9016 - Dunedin - Dunedin Hospital
NCT04973605
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) (
BGB-11417-105
)
anti-CD38 monoclonal antibody
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
ACT
2605 - Garran - The Canberra Hospital
NSW
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
WA
6000 - Perth - Royal Perth Hospital
NCT03590171
Paed
Phase 2
Recruiting
International Study for Treatment of High Risk Childhood Relapsed ALL 2010 A Randomized Phase II Study Conducted by the Resistant Disease Committee of the International Berlin, Frankfurt, M\xFCnster (BFM) Study Group (
IntReALL-HR-2010
)
Bortezomib
cancer therapy
cancer therapy,proteasome-targeting
proteasome inhibitor
+ cancer therapy,proteasome-targeting
Acute lymphoblastic leukaemia
VIC
3168 - Clayton - Monash Medical Centre
ACTRN12624001468516
Haem
Phase 2
Not yet recruiting
A phase 2 study of the feasibility and efficacy of at home patient administered subcutaneous daratumumab in patients with relapsed multiple myeloma (
Dara@Home
)
anti-CD38 monoclonal antibody
+ cancer therapy,proteasome-targeting
Multiple myeloma
ACTRN12622001366741
Haem
Phase 2
Recruiting
Investigating the efficacy of Risk Directed front-line therapy for Multiple Myeloma incorporating Selinexor: The
RIDDLE-M-X
trial
XPO1 inhibitor
+ cancer therapy,proteasome-targeting
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2640 - Albury - Border Medical Oncology Research Unit
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
ACTRN12621001458820
Haem
Phase 1
Not yet recruiting
Phase I Clinical Trial to Determine Dosing Schedule of Hydroxychloroquine in Participants with Multiple Myeloma and Partial Response or Less to Carfilzomib (
CHARMM
)
anti-malarial agent
proteasome inhibitor
Cancer
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
ACTRN12611000605998
Haem
Phase 2
Recruiting
A Phase II trial of bortezomib and dexamethasone in renally-impaired patients with untreated multiple myeloma. (
The-BRIM-Trial
)
glucocorticoid
proteasome inhibitor
Multiple myeloma
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (13)
Not yet recruiting (3)
Enrolling by invitation (1)
Recruitment Country and State
VIC (14)
NSW (12)
QLD (9)
WA (8)
NZ (3)
SA (2)
ACT (1)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (2)
Phase 2 (6)
Phase 3 (8)
Trial Type
Haem (16)
Paed (1)
Cancer Therapy Class
proteasome
100%
cereblon
71%
CD38
59%
BCMA
29%
GPRC5D
6%
CS1
6%
PD-1
6%
PD-1/PD-L1
6%
Bcl2
6%
XPO1
6%
Facility
3004 - Melbourne, Southbank - Alfred Health (8)
3065 - Fitzroy - St Vincent's Hospital Melbourne (8)
2170 - Liverpool - Liverpool Hospital (5)
6150 - Murdoch - Fiona Stanley Hospital (4)
3000 - Melbourne - Peter MacCallum Cancer Centre (4)
3121 - Richmond - Epworth Freemasons Hospital (3)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (3)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (3)
2050 - Camperdown - Chris O'Brien Lifehouse (3)
3168 - Clayton - Monash Medical Centre (3)
4575 - Birtinya - Sunshine Coast University Hospital (3)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (3)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
2139 - Concord - Concord Repatriation General Hospital (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
3002 - East Melbourne - Epworth Freemasons (2)
2500 - Wollongong - Wollongong Hospital (2)
4217 - Benowa - Pindara Private Hospital (2)
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
4102 - Woolloongabba - Princess Alexandra Hospital (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (2)
2145 - Westmead - The Children's Hospital at Westmead (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
4215 - Southport - Gold Coast University Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
6005 - West Perth - Perth Blood Institute (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
NZ.0622 - Takapuna - North Shore Hospital (1)
NZ.3210 - Hamilton - Waikato Hospital (1)
2500 - Wollongong - Cancer Care Wollongong (1)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
2605 - Garran - The Canberra Hospital (1)
6000 - Perth - Royal Perth Hospital (1)
2640 - Albury - Border Medical Oncology Research Unit (1)
3066 - Epping - Northern Hospital (1)
Cancer Type
Cancer
Haematological malignancy
Plasma cell disorder
Multiple myeloma
AL amyloidosis
Amyloidosis
Acute lymphoblastic leukaemia
Leukaemia
Lymphoid leukaemia
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy